FABP5 and neoplasm: As primary CCa tumour samples can be easily obtained by transvaginal biopsy so that the expression levels of FABP5 can be tested before treatment, the combination of FABP5, BMI, and LVSI can be applied to assess LNM in CCa patients before the first treatment.